BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

860 related articles for article (PubMed ID: 32567373)

  • 1. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
    Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
    Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy.
    Zhao P; Deng Y; Gu P; Wang Y; Zhou H; Hu Y; Chen P; Fan X
    Exp Eye Res; 2013 Feb; 107():65-73. PubMed ID: 23219871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
    Janssen JAMJL; Smith TJ
    Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-Like Growth Factor Pathway and the Thyroid.
    Smith TJ
    Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
    Antonelli A; Ferrari SM; Giuggioli D; Ferrannini E; Ferri C; Fallahi P
    Autoimmun Rev; 2014 Mar; 13(3):272-80. PubMed ID: 24189283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ
    Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
    Fernando R; Caldera O; Smith TJ
    Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.
    Fernando R; Smith TJ
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e4037-e4047. PubMed ID: 35809263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
    Smith TJ
    J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
    Smith TJ
    Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
    Slentz DH; Nelson CC; Smith TJ
    Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2021 update on thyroid-associated ophthalmopathy.
    Neag EJ; Smith TJ
    J Endocrinol Invest; 2022 Feb; 45(2):235-259. PubMed ID: 34417736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
    Morshed SA; Ma R; Latif R; Davies TF
    Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
    [No Abstract]   [Full Text] [Related]  

  • 14. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
    Ali F; Chorsiya A; Anjum V; Ali A
    Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
    Ding Y; Yang S; Gao H
    Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.
    Wang Y; Smith TJ
    Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1735-48. PubMed ID: 24651704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs based regulation of cytokine regulating immune expressed genes and their transcription factors in COVID-19.
    Khokhar M; Tomo S; Purohit P
    Meta Gene; 2022 Feb; 31():100990. PubMed ID: 34722158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
    Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
    Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.